Partnering with the largest cancer research center in the US & gaining access to their library of binders.
OmniCAR will be paired with unique IP developed by MD Anderson Cancer Center that enable OmniCAR to attack both internal and external targets of the cancer cells, further consolidating OmniCAR as the leader in next generation cell therapy tech.
MD Anderson will manufacture the cells for the collaboration, all expenses will be split 50/50,
Both parties will share ownership of the resultant therapeutic product.
My post yesterday has firmed a whole lot in the space of 17 hours...Steven is using words like culmination and inflection...When the CEO states to shareholders via email that he will be participating in the CR it's pretty evident to me which way he expects this inflection point to break...That's upwards.
PTX Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
